Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent.
- Body mass index between 21.0 kg/m^2 and 29.9 kg/m^2 (both inclusive).
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion Criteria:
- Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening.
- Use of tobacco and nicotine products, defined as any of the below:1) Smoking more than 5 cigarettes or the equivalent per day.2) Not willing to refrain from smoking and use of nicotine substitute products during the inpatient periods.
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
- History (as declared by participant) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
- Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by participant).
- Presence or history (as declared by participant) of pancreatitis (acute or chronic).
Sites / Locations
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
Semaglutide D 50 mg
Semaglutide C 50 mg
2 x Semaglutide C 25 mg
Semaglutide E 50 mg
Semaglutide F 50 mg
Participants will receive once daily semaglutide D formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 2 x 25 mg (week 13-16)
Participants will receive once daily semaglutide tablets in a dose escalating manner for 16 weeks: A) Semaglutide C formulation: 2.4 mg (week 1-2), 5.6 mg (week 3-4) and 11.2 mg (week 5-8). B) Semaglutide E formulation: 25 mg (week 9-12) and 50 mg (week 13-16)
Participants will receive once daily semaglutide F formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)